JNEF said:
yes but nobody is pushing dnp on you, people should be allowed to discuss it and make their own decision while researching. you sound like "big brother" remember you can also die from an asprin overdose.
dnp is not safe to use—you can use it in manner that lowers the risk of death perm side effects.
to compare it to aspirin is flawed---the line between a therapeutic and a deadly dose is not comparable to dnp.
while asprin can be fatal in doses over 55,000 mg (88x-166x therapeutic dose) (assume 235lb man)
dnp can be fatal at 1g-3g* ( <1x-7x doses taken by bbs)
with a possibilty that the line between fat loss and death is less than 1x the dose taken and the product produced by an UG, how can that be even considered safe to take or being able to used in a safe manner by any stretch? esp when VVVVV
the signs and symptoms of acute poisoning are the same as expected for fat loss**
and btw, don't take asprin while on dnp***
*The fatal dose in adults is about 1 to 3 g by mouth, and 3 g has proved fatal even in divided doses over a period of 5 days. [Gosselin, R.E., R.P. Smith, H.C. Hodge. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984., p. III-157; The acute fatal dose of dinitrophenol /SRP: Unspecified mixture of isomers/ is approximately 1 g.[Dreisbach, R.H. Handbook of Poisoning. 11th ed. Los Altos, CA: Lange Medical Publications. 1983., p. 127}
**Signs and symptoms of acute poisoning in human beings include nausea, restlessness, flushed skin, sweating, rapid respiration, tachycardia, fever, cyanosis, and finally, collapse and coma. The illness runs a rapid course; death or recovery occurs within 24 to 48 hours. If production of heat exceeds the capacity for its dissipation, fatal hyperthermia may result. Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1691
***"Salicylates, which contain a phenolic group, must be avoided during treatment for exposure to dinitrophenols." [Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1691]